Objective This work evaluates the potential of using fresh milk to deliver theophylline to children. Methods Theophylline-fresh milk systems were prepared using different solids ratios (0 : 1-1 : 0) and three fat contents in commercial milks (low, medium and high), which were spray-dried at different inlet air temperatures (T inlet -105, 130 and 150°C). The process was evaluated for yield and the resulting powders for moisture content (MC), particle size and shape, density and wettability. Theophylline-milk potential interactions (differential scanning calorimetry (DSC) and FT-IR) and chemical (theophylline content) and microbiological stability of powders (shelf and in-use) were also evaluated. Key Findings The production yield (13.6-76.0%), MC (0.0-10.3%) and contact angles in water (77.29-93.51°) were significantly (P < 0.05) affected by T inlet , but no differences were found concerning the mean particle size (3.0-4.3 lm) of the different powders. The milk fat content significantly (P < 0.05) impacted on the density (1.244-1.552 g/cm 3 ). Theophylline content remained stable after 6 months of storage, before extemporaneous reconstitution. After reconstitution in water, low-fat milk samples (stored at 4°C) met the microbial pharmacopoeia criteria for up to 7 days. No theophylline-milk components interaction was observed. Conclusion Spray-dried milk-composed powders may be used as vehicles for theophylline delivery in paediatrics following further characterization and in-vivo evaluation.
Introduction
A paediatric patient belongs to a distinct and heterogeneous group regarding pharmacotherapeutic requirements. [1, 2] It is well-established that children are not small adults, and therefore, drug formulations for paediatrics should be adapted to suit children's age, size and physiology, as well as treatment needs. Medicines' design is therefore critical to achieve not only safe and accurate dosing of drugs, but also to enhance compliance and improve clinical outcomes in children. To tackle this problem, new paediatric regulations and development programmes have recently been issued by the European Medicines Agency (EMA) [3] and the World Health Organization (WHO). [4, 5] Children are, however, especially challenging [6] as they are continually growing up, thus presenting constantly evolving pharmacokinetic parameters, and many existing medicines were not designed or tested ab initio having these considerations in mind. Moreover, many drugs are unavailable as paediatric formulations, requiring the use of unlicensed (off-label) medicines, by manipulation of existing dosage forms designed for adults. Often, these are compounded with excipients which are toxic to children and are administered without considering that paediatric patients do not have fully developed enzymatic and immunologic systems.
These dosage forms are preferred among children (<5 years old) due to their ease on swallowing and dose adjustment, but can compromise the patient's compliance (e.g. bitter taste), suffer from dose inaccuracy and lack long-term chemical, physical and microbiological stabilities. Smallsized multiunit solid dosage forms, such as minitablets, [9, 10] pellets [11] and granules, [12] which do not present the disadvantages discussed for liquids, become a better option in grammar school children's age (>6 years old) due to the ease of administration. [2, 13] However, as discussed before, the paediatric group encompasses so many different individual characteristics and is so diverse that it is almost impossible to develop a single formulation which is accepted across the group. [2] Compliance with drug therapy in paediatrics is related to the acceptability of the formulations by patients. In some situations (e.g. bitterness of the API, active pharmaceutical ingredient), nurses, parents and even caregivers are encouraged to mix the medicines with food (e.g. juices and infant milk formulas) disregarding drug stability issues. [14] In this study, milk was chosen as a matrix for potential drug delivery in paediatrics because it is a worldwide accepted food (in fact, the primary nutritional source in the newborns) which presents good organoleptic and physicochemical properties for the intended use. As a complex system -milk is simultaneously a solution (dissolved proteins, minerals and vitamins), a suspension (whey proteins) and an emulsion (lipids and lipophilic vitamins) À it incorporates drugs with different solubilities and thus represents a good matrix for paediatric drug delivery. In fact, milk components (e.g. caseins) have already been used as vehicles for bioactives [15] but a few studies have explored its potential in paediatric drug delivery. [16] Milk-based oral formulations recently described in the literature consisted of alkaline/ethanolic solutions, containing different drugs, which were mixed with fresh milk immediately before administration to patients [17] or used skimmed milk to formulate solid dispersions of poorly water solubility APIs. [18, 19] In these cases, extra excipients will be needed in the formulation, increasing the risk of toxicity or simply increasing the complexity of the final product.
Milk is commercially available as powdered or fresh milk. The latter can be easily converted into powdered milk by spray drying, which is the most common method for dehydrating milk. The process promotes the stability of the final product and, at the same time, lowers the production costs due to the very short time of heat contact and high rate of evaporation. [20, 21] Consequently, it is possible to hypothesize that a drug-milk system can be converted into a powdered formula by spray drying. The final product is expected to be both more stable in the long term (particularly by comparison with liquid dosage forms) and amenable to be used in a broader age group of patients (as compared to other solid dosage forms). The use of fresh, as compared to powdered milk, to incorporate the drug presents the advantage of promoting uniformity of contents and solubilization of poorly water-soluble drugs. Theophylline (1,3-dimethyl-7H-purine-2,6-dione) was considered in the study as a model drug, based on therapeutic relevance in the treatment of acute and chronic asthma in children, [22] and the possibility of extrapolating these results to other drugs that are known for their narrow therapeutic index.
The novelty of the work resides on the use of spray-dried fresh milk as a platform to deliver drugs in paediatrics, addressing three main concerns of health authorities [23] regarding paediatric medicines: (1) safety of excipients, (2) appropriateness of formulation and dosage form according to the age group considered and (3) dosing flexibility, accuracy and practical handling.
Materials and Methods

Materials
Fresh commercial milks (Mimosa; Lactogal Produtos Alimentares S.A., Porto, Portugal) with different fat contents (per 250 ml), low-fat milk (LFM À 0.3 g), middle-fat milk (MFM À 4.0 g) and high-fat milk (HFM À 9.0 g), were used in the study. Anhydrous theophylline, diiodomethane, p-aminobenzoic acid (PABA) and acetonitrile (HPLC grade) were all from Sigma Life Science (Sintra, Portugal), ammonium acetate (Merck, Darmstadt, Germany) and methanol (Fischer Chemicals AG, Zurich, Switzerland). Deionized water (W, 18.2 MΩ cm, Milli-Q system; Merck Millipore, Massachusetts, USA) was used throughout the study. All other reagents were of analytical grade.
Methods
Preparation of theophylline: milk systems
A theophylline stock solution (7.5 mg/ml deionized water, 900 rpm, 30 min) was used to incorporate known amounts of drug into constant volumes of each type of milk to obtain theophylline : milk solids ratios of 0.08 : 1, 0.16 : 1, 0.31 : 1, 0.62 : 1 and 1 : 1 (w/w, Table 1 and Annex 1). Controls of fresh milks and aqueous theophylline solutions (0 : 1 and 1 : 0) were considered. Altogether theophylline was present in quantities from 0 to 2.5 g per 2.5 g of powdered milk.
Spray drying
Spray drying of theophylline in milk systems was performed in a Mini Spray-Dryer B-191 (B€ uchi Labortechnik GmbH, Flawil Switzerland). The feed solutions were atomized (1-mm-diameter static nozzle) using a feed liquid rate of 4 ml/min (i.e. 20%), an atomizing airflow rate of 600 l/h and a constant aspiration rate of 100%; settings were kept constant throughout the study. Three different inlet/outlet air temperatures (Tinlet,/Toutlet) were used: 105/68, 130/87 and 150/100°C. The outlet air temperature was recorded after the beginning of the drying process, and although it depends on the instrument settings, variations were smaller than AE1°C. Theophylline controls were atomized at a single inlet/outlet air temperature (130/87°C).
The solutions were fed into the spray-dryer chamber, once the desired inlet temperature was achieved. The spray-dried samples were collected and stored at room temperature (24 AE 1°C) and controlled humidity (RH = 65%).
Characterization of spray-dried powders and process
Yield and moisture content of powders. The yield of the process was obtained from the ratio between the mass of powder collected from the outlet chamber and the sum of ), surface free energy; MC, moisture content (%); q, particle density (g/cm milk solid components and theophylline masses; moisture content (MC) of dried powders was determined by the water loss on drying of powders dried in an oven (Memmert, Schwabach, Germany) at 75 AE 3°C, until constant weight.
Particle size and shape analysis. The mean particle's diameter by number was determined by optical microscopy (BX51; Olympus, Tokyo, Japan), after suspension of powder specimens in liquid paraffin. To guarantee a normal distribution of data, more than 200 particles were measured from photographs (five different fields; 509 magnification, Olympus Stream Essentials Software; Olympus) and classified as spherical or non-spherical (ICH Topic Q4B [24] ) upon observation of random fields by scanning electronic microscopy (SEM after coating with chromium; JEOL JSM-T330A; JEOL, Peabody, MA, USA).
Density. Helium pycnometry (AccuPyc 1330; Micromeritics, Norcross, GA, USA) was used to measure the density of spray-dried milk powders (n = 3).
Contact angle and surface free energy determinations. Contact angles (h) were measured by tensiometry (Wilhelmy plate method, K100; Kr€ uss GmbH, Hamburg, Germany) once spray-dried powders were made to adhere to a rectangular support (20 9 20 mm). The testing liquids (water, h W and diiodomethane, h D ) were placed in a glass jar (ca 50 cm 3 ) which was raised at 6 mm/min until the plate was submersed for 2 mm at 25 AE 0.5°C (n = 3; Thermo Haake GmbH, Karlsruhe, Germany). Contact angles and surface free energies were calculated from the Wilhelmy equation and the works of adhesion (Wa) and cohesion (Wc), and spread coefficients were calculated for both the raw materials (different fat content milks and theophylline) and dried samples according to Wu equations (LabDesk v. 3.2; Kr€ uss GmbH), as described in the literature. [25] Evaluation of potential interaction between theophylline and milk components Fourier transform infrared spectroscopy. Infrared spectra were collected for raw materials and processed powders (Affinity-1 Fourier transform infrared spectroscopy (FT-IR); Shimadzu Corp., Kyoto, Japan) in potassium bromide discs (1 mg sample in 100 mg potassium bromide) prepared by gently grinding the materials in a mortar before compaction (40 kN column (250 9 4 mm internal diameter; particle size 5 lm) and a Purospher C18 guard column (4 9 4 mm internal diameter; particle size 5 lm) were used. PABA (5 lg/ml) was included in every sample as an internal standard (IS). The eluent (10 mM ammonium acetate buffer: acetonitrile: methanol in 90 : 5 : 5 v/v/v) was run under isocratic conditions at 1 ml/min flow rate. Appropriately diluted samples were centrifuged (670g/10 min) before injection (20 ll) and analysed in triplicate. Standard solutions of theophylline (0.2-75 lg/ml) and PABA working solution (100 lg/ml) were prepared in water. The method was previously validated for specificity, linearity, accuracy, precision and recovery, according to ICH guidelines. [26] Stability studies
Shelf stability of powders and in-use stability, after reconstitution in water, was performed in a random set of seven spray-dried samples (of 54 possible samples, according to a complete factorial design of experiments). Powders were manufactured in the same week the study started (time 0) and were retested (theophylline content and microbial burden) after 6 months of storage (25°C/ 65% of RH). Powders (2 g) were reconstituted in water (15 ml), in a 20-ml amber flask and shaken for one min and equally divided into two other containers (stored at 4 and 25°C, respectively). At specific time points (0, 1, 2, 7, 14 and 28 day), 1 ml aliquot of each extemporaneous preparation was taken for drug quantitation and microbiological assay.
Total aerobic viable microorganisms, total number of yeasts and moulds, and absence of Escherichia coli (in both powders and reconstituted samples) were assessed according to the European Pharmacopeia. [27] Statistical analysis Analysis of data was performed using SPSS v.22.0 (IBM â , New York, USA) for descriptive analysis of categorical and scalar variables. The results were further analysed using one-way ANOVA followed by post hoc Bonferroni's test (P < 0.05). Unless otherwise stated, data are represented as mean with coefficients of variation smaller than 2% for all experiments.
Results
Properties of the spray-dried powders and characterization of the production process
Results obtained for the different medicinal powders produced by varying the milk fat content and the amount of theophylline, as well as for samples containing only milk (LFM, MFM and HFM), or theophylline, used as controls are given in Table 1 and Annex 1 and statistical analysis in Table 2 .
Yield and moisture content
Aqueous solutions of theophylline containing the same fractions as those present in the studies with different milks (controls) have shown yields within the range of 19.18-30.04% and residual water content within the range of 0.4-2.0% (Annex 2). These experiments have shown acceptable MCs but low yields of collected theophylline, anticipating the need of optimization for industrial scaling up. The spray-dried milk powders, regardless of the variables considered, presented a yield in the range of 25.2-73.3 (Table 1) . Powders atomized at 130°C presented the highest yields, which were significantly different (P < 0.05, Table 2 ) from those powders produced at other temperatures, suggesting that T inlet is a key factor in the manufacture of the product. In contrast, neither the theophylline fraction in the powder nor the fat content of the fresh milk affected the yield of the powders (P > 0.05, Table 2 ). The MC of the spray-dried milk powders ranged between 0.0% and 10.3%, and as the T inlet increased, the MC of powders decreased significantly (P < 0.05). The absence of significance of either fat content or theophylline fraction on the yield or MC was anticipated due to the inexistent relationships between these variables (Table 1) .
Particle size and shape
Microscopic evaluation of powdered samples revealed that, overall, particles acquired a spherical shape on drying (Figure 1a and 1b) . However, some samples have shown suspended needle shaped and crystalline particles, assumed (Table 1 ). The variability observed for the data collected from this set of experiments was reflected on the absence of significant effect on the size of particles by each of the three factors considered (T inl , fat content and theophylline fraction) ( Table 2 ).
Density
The density of powders was in the range 1.426-1.552 g/cm 3 for LFM, 1.386-1.455 g/cm 3 for MFM and 1.244-1.437 g/cm 3 for HFM (Table 1) . This property was significantly affected by the fat content of milk (P < 0.05) but neither the theophylline fraction nor T inlet significantly influenced the density of the powders (Table 2 ). However, although not significant, a slight increase in the density was observed with the increase in theophylline fraction, in line with the density of control samples (milk only, data not shown).
Surface properties of powders
The contact angle of theophylline in water (77.33°) was smaller than that of pure milk powders (79.76-93.51°). In average, LFM produced medicinal powders with lower contact angles in water (80.62-87.17°) than MFM (79.76-93.45°) and HFM (77.29-93.51°). Table 1 summarizes the results from contact angles, c s and c p , respectively, total and polar component of surface energy, of each spray-dried powder. The two interrelated properties were significantly affected by T inlet , and marginally by the fat content of milk. Only the polar component (c p ) was also significantly affected by the milk fat content (P < 0.05), with the MFM samples being significantly different from the other two ( 2 , respectively) than the ones atomized at the other inlet air temperatures (130 and 150°C). After resting at room temperature (25°C, overnight), these values decreased slightly (data not shown) reflecting some stabilization of the powders' surfaces immediately after processing. To anticipate the interaction between theophylline and the matrix formed by milk components in the drug-loaded dried particles, the works of cohesion (W c ) and adhesion (W a ) were calculated for the controls (theophylline and milk) ( Table 3 ) increasing with the content of fat in the milk. These values were in line with those obtained for the dried powders and confirm the spreading of milk components on theophylline molecules.
Evaluation of drug-milk potential interaction
Fourier transform infrared spectroscopy
The FT-IR spectra from all samples and controls were evaluated but, as the different T inlet considered did not produce products with different spectra, only the spectra of the spray-dried milk powders atomized at 105°C are presented as an example (Figure 2 group due to the stretching of the fatty esters molecules. [29] When the fraction of theophylline increased in the dried powders, the signals due to the molecule of theophylline started to be more intense than the signals due to the milk components, as expected. For the 0.08 : 1 and 0.16 : 1 solids ratio samples, the N-H stretching at 3120.96 cm
À1
was not observed. The potential formation of an imine group due to the interaction between theophylline and milk components in the dried powders, reflected by new bonds formation, would have been observed in the 1647-1630 cm À1 region; but it was neither observed in samples considered immediately after spray drying or after storage (6 months) of dried powders.
Differential scanning calorimetry
The thermograms obtained from calorimetric studies of the spray-dried milk samples manufactured at 150°C are shown in Figure 3 . For this process temperature, theophylline presented a sharp endotherm event at 272.75°C (positive control), whereas spray-dried milk powders presented a broad band that corresponds to the dehydration of the samples (40-110°C) and two other small bands corresponding to milk components, such as lactose or proteins [30] For the powders produced from middle-and high-fat milks, endothermic (on heating the sample) and exothermic (on cooling) events were also observed between 30 and 40°C (melting followed by recrystallization of fat content). Above 0.31 : 1 solids' ratio samples, a broad band started to appear between 233.30 and 249.11°C. As the theophylline fraction increased in the formulation, a shift of this peak to higher temperatures between 257.68 and 266.88°C was observed. The endothermic events characteristic of the milk components (negative controls) were also observed in the spray-dried milk powders, although the enthalpies of fusion were higher for the latter. The glass transition temperature (T g = 30.72°C) was distinctly observed in the LFM samples in contrast to the MFM and HFM samples. It is worth noting that no other differences in the thermograms were observed for the different temperatures. Although thermograms were complex due to the complexity of the samples, the patterns of the curves were reproducible particularly when the second heating stage was applied to samples.
Quantification of theophylline in powders
The theophylline assay in freshly prepared theophyllinemilk solutions has shown a slight increase in drug content as the drug fraction increased in formulations, independently of the other factors (T inlet and fat content of milks, data not shown). The quantification of theophylline in the spray-dried powders has shown that T inlet and milk fat content were not significant and did not affect the recovery and quantification of theophylline from samples (Table 1) . A dramatic decrease in drug content above 0.31 : 1 was obtained and became particularly significant (P < 0.05) for the 0.62 : 1 and 1 : 1 ratios, and higher processing temperature and milk fat content (Table 2) suggesting that drug recovery from samples was not complete. Overall, theophylline content was within 2-7% variation in the different powder samples assayed (data not shown).
Stability
The stability in-use was assessed after the reconstitution of dried powders in water immediately after production. After storage at room temperature (25°C), microbial criteria were met at day one by all samples, regardless of fat content and processing conditions. At 4°C, microbial criteria were met by all samples up to 2 days, but only LFM samples met the criteria 7 days after reconstitution. Yeasts and E. coli were absent in every sample tested. Theophylline content in solution remained stable over the 28 days of test, regardless of fat content and microbial growth (not shown). It is also worth to mention that samples dried at lower inlet air temperatures presented lower microbial growth.
Regarding the medium-to long-term stability of spraydried powders, microbial criteria were met only by LFM samples and theophylline quantification has shown that there was no decrease in content after 6 months of storage.
Discussion
It was expected that as the inlet air temperature increased, the yield also increased, but that was not verified, in contrast to some previous studies [31] in which only the effect of T inlet was considered. However, the complex matrix (e.g. protein, fat and lactose) used in the present work can justify the results obtained. For instance, it is known that powdered hygroscopic lactose is sticky in the presence of residual water [20] and that the yield at high T inlet [32] was diminished. Furthermore, molten milk fat concentrated at the surface of the particles [21, 33] at high temperatures (e.g. 150°C) increases stickiness of the product to the drier's wall with a decrease in yield. The yield of spray-dried theophylline (control) was significantly smaller than those of drug-loaded milk powders, suggesting that during the process, theophylline molecules have bound to the milk components (e.g. proteins [15] ), thus reducing drug loss on drying.
The powder MC may have a significant impact on the long-term stability, both in terms of drug degradation and microbial growth. [34] As T inlet increased, the residual water in the spray-dried powders decreased, as corroborated by other studies. [35, 36] After spray drying, lactose becomes largely amorphous and highly hygroscopic, [20] as observed in LFM samples, showing a T g (ca 30.72°C) considerably lower than the T g of amorphous lactose (97-116°C), [20, 37] emphasizing the care required to assure optimal storage conditions (RH and temperature) of the powders. This T g was neither found in MFM, nor in HFM powders, which might have embedded the lactose or simply overlap the thermic event due to the proximity of the melting range of fat components. [37] Sizing and shaping of particles by microscopy confirmed the expected spherical shape and narrow size distribution of dried particles (3.0-4.3 lm in diameter) which are appropriate for reconstitution in water. [36] These properties were independent of the factors considered (T inlet , theophylline fraction) in contradiction to other studies [31, 36] which have concluded that particle size was influenced by different T inlet because higher temperatures of atomization led to an expansion of the final particles, whereas lower temperatures promoted shrinkage of their structure. In the present case, the fat component may have accommodated the impact of T inlet on particles' size.
The density of spray-dried powders was only affected by the fat content of the fresh milk, with the LFM samples presenting the highest values, in contrast to the HFM samples, due to the fact that fat is less dense than other components in the powders. It was not surprising that LFM samples were more hydrophilic (lower h w ) and presented higher wettability (better redispersibility in water), in line with what was observed before with solid dispersions of poorly water-soluble drugs. [19] During particle formation, it is possible that protein, either as free molecules or in micelles, be deposited on the surface of the forming particle, lowering their surface energy. On the contrary, higher fat content milk, in which fat globules have the ability to disperse and migrate to the surface of the particles, produced a hydrophobic surface. [38] Interestingly, some MFM samples have shown higher contact angles than HFM samples. One can hypothesize that, throughout drying, the rearrangement of the milk components in these two types of milk was different leading to different fat/protein surface compositions. The residual water might have been the justification of the lowering h w of HFM samples dried at 105°C which decreased the fraction of fat with impact on the redispersibility in water. Spreading coefficients indicate that milk components had a tendency to spread over theophylline making the properties of bulk particles independent of theophylline fraction, the latter more difficult to extract and quantify.
Data from the FT-IR spectra were sensitive to the ratio between theophylline and milk components. As theophylline fraction increased, particularly above 0.31 in MFM and HFM powders, the signal due to milk components decreased until complete replacement by the theophylline signal, particularly in the region observed for the peaks of the proteins' amides I and II in higher fat milks. This observation was harder to verify in spray-dried particles due to the fact that such particles presented a fat rich surface, particularly evident in MFM and HFM, with broad peaks overlapping those of the proteins. [39] [40] [41] On the contrary, in powders with low theophylline fractions (e.g. 0.08 and 0.16), the presence of the N-H stretching in the region of 3120.96 cm À1 was difficult to observe due to a dilution effect and overlap of the drug's output. This means that the absence of peaks is due to the fractions of components in the powders, and not to the interaction between any component of the milk and theophylline. These observations are in agreement with that of a solid dispersion made of powdered skimmed milk as carrier of valsartan, a drug molecule which presents an amine group, as theophylline does. [19] The potential interaction of lactose with theophylline (e.g. Maillard's reaction) [42] was evaluated immediately after drying and 6 months later. Likely this potential interaction would have been reflected by the N-H bond of the drug and the O-H of the lactose. Data from FT-IR in the region of 1647-1630 cm À1 revealed that no imine group was formed; thus, no reaction was deemed to have occurred. The DSC thermograms did not show any thermic events, particularly between 100 and 150°C or at higher temperatures (e.g. 220°C) [43] temperatures at which possible products of degradation might have been formed, as observed for other drugs and dosage forms. [44, 45] The presence of milk fat and protein components may have prevented the interaction between the drug and lactose. [38] The quantification of theophylline in dried powders indicated that T inlet and milk fat content did not affect the quantity of theophylline in samples, in contrast to the fraction of theophylline. However, the amount of theophylline in dried powders was not entirely reflected in powders above 0.31 : 1 ratio, particularly at 0.62 : 1 and 1 : 1 ratios (P < 0.05). However, as the analytical technique was previously validated, the partial recovery of theophylline may have been due to uncollected theophylline particles, that is partial loss of theophylline to the exhaust of the spray drier, or an incomplete extraction of theophylline from the particles. This observation is supported by the low yields obtained when theophylline was dried alone from solutions. If a correlation between these observations is made, then one can say that milk decreases the loss of theophylline during the drying process by incorporation of theophylline molecules within milk components.
The microbiological evaluation of the reconstituted powder (in-use stability) has shown that the Pharmacopeia criteria were met on the first day for samples stored at 25°C. After 2 days of reconstitution, criteria were met by all samples at 4°C, and after 7 days, only LFM samples met the criteria. These results are comparable to that (13.7 days) obtained for pasteurized skimmed milk (LFM), stored at 5°C. [46] Theophylline content in solution remained constant throughout the study in every extemporaneous sample. The lower microbial growth presented by samples dried at lower inlet air temperatures suggests that the longer time taken to dry the droplets, resulted in a smaller microbial survival rate.
In powders stored for 6 months, theophylline also remained chemically stable, but microbiological specifications were no longer observed, except for LFM. However, non-compliance was not dependent on MC, as LFM with a 6.4% MC passed the test. Samples with lower milk fractions were closer to acceptability than the others, which is not surprising if one considers that milk is an excellent microbial culture media.
Conclusions
The study has confirmed the potential of using fresh milk to produce powders as a solid dosage form to deliver drugs to children, as such or after extemporaneous reconstitution in water (or indeed, as a the starting point for other dosage forms). The work highlights an innovative approach of using milk as a likely alternative platform to deliver drugs to the paediatric population of different age groups. The process and product presents several advantages, namely the fact that drug is mixed with milk only, decreasing the toxicity concerns of the final formulation and incorporation of drug in solution promotes uniformity of content. An oral solid dosage form is suggested as theophylline content remained stable after 6 months of storage of powders, as well as after reconstitution in water. In-use and shelf-life stability of powders showed that LFM samples met the microbial criteria, at 4°C for 7 days and at 25°C for 6 months, respectively. Furthermore, no drug-milk interactions were observed. The use of different fresh milks, preferably LFM, should be considered as a possible drug powder-solution formulation that, due to its likeliness to a well-known food to children, would result in increased patient's compliance. For parents, nurses and caregivers, this composed pharmaceutical powder would be easy to prepare, requiring only reconstitution in water (simple due to the low contact angles exhibited), thus minimizing the problems related to dose flexibility and accuracy.
To fully establish this approach, a further characterization of the system (namely in terms of drug entrapment and interaction between low solubility/hydrophobic drugs and milk fat components) and in-vivo studies (e.g. to investigate the influence of fat on the digestion and release of the drug) are warranted. Furthermore, as the source of milk is likely to affect the final product, special attention should be paid to the specifications of the fresh milk used, to guarantee reproducibility.
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Annex 1 Preparation of theophylline: milk systems
